Cox regression analyses
| Variable . | Time-independent analyses . | Time-dependent analyses . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Univariable Cox regression analyses | ||||||
| Preemptive rituximab | 0.23 | 0.06-0.94 | .040 | 0.41 | 0.10-1.66 | .2 |
| Log-transformed peak EBV viral load (IU/mL) | 1.31 | 1.20-1.42 | <.001 | - | - | - |
| Peak plasma EBV viral load categories (IU/mL) | - | - | - | - | - | - |
| Detectable but not quantifiable | - | - | - | - | - | - |
| <1000 | 0.62 | 0.32-1.20 | .2 | - | - | - |
| 1000-4000 | 1.94 | 0.90-4.20 | .092 | - | - | - |
| >4000 | 4.90 | 2.56-9.40 | <.001 | - | - | - |
| Duration of EBV DNAemia (mo) | 1.01 | 1.00-1.01 | .003 | - | - | - |
| Time from SOT to EBV reactivation (mo) | 0.99 | 0.98-0.99 | <.001 | - | - | - |
| High-risk D/R serostatus | 5.13 | 3.29-8.00 | <.001 | - | - | - |
| D/R serostatus∗ | - | - | - | - | - | - |
| Intermediate risk | - | - | - | |||
| High risk | 5.34 | 3.39-8.40 | <.001 | - | - | - |
| Low risk | 2.02 | 0.62-6.56 | .2 | - | - | - |
| High-risk organ type† | 3.27 | 1.93-5.52 | <.01 | |||
| Age of <18 years at transplant | 2.31 | 1.50-3.57 | <.001 | - | - | - |
| Multivariable Cox regression analysis | ||||||
| Preemptive rituximab | 0.16 | 0.04-0.65 | .011 | 0.25 | 0.06-1.04 | .056 |
| Log-transformed peak EBV viral load (IU/mL) | 1.26 | 1.15-1.38 | <.001 | 1.26 | 1.15-1.37 | <.001 |
| Duration of EBV DNAemia (mo) | 0.99 | 0.99-1.00 | .076 | 0.99 | 0.99-1.00 | .043 |
| Time from SOT to EBV reactivation (mo) | 0.99 | 0.98-1.00 | <.001 | 0.99 | 0.98-0.99 | <.001 |
| D/R serostatus∗ | - | - | - | - | - | - |
| Intermediate risk | - | - | - | - | - | - |
| High risk | 3.08 | 1.78-5.31 | <.001 | 3.11 | 1.82-5.32 | <.001 |
| Low risk | 1.62 | 0.47-5.57 | .4 | 1.71 | 0.50-5.85 | .4 |
| High-risk organ† | 3.71 | 2.03-6.78 | <.001 | 3.69 | 2.03-6.71 | <.001 |
| Age of <18 years at transplant | 1.14 | 0.65-2.01 | .7 | 1.10 | 0.63-1.94 | .7 |
| Variable . | Time-independent analyses . | Time-dependent analyses . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Univariable Cox regression analyses | ||||||
| Preemptive rituximab | 0.23 | 0.06-0.94 | .040 | 0.41 | 0.10-1.66 | .2 |
| Log-transformed peak EBV viral load (IU/mL) | 1.31 | 1.20-1.42 | <.001 | - | - | - |
| Peak plasma EBV viral load categories (IU/mL) | - | - | - | - | - | - |
| Detectable but not quantifiable | - | - | - | - | - | - |
| <1000 | 0.62 | 0.32-1.20 | .2 | - | - | - |
| 1000-4000 | 1.94 | 0.90-4.20 | .092 | - | - | - |
| >4000 | 4.90 | 2.56-9.40 | <.001 | - | - | - |
| Duration of EBV DNAemia (mo) | 1.01 | 1.00-1.01 | .003 | - | - | - |
| Time from SOT to EBV reactivation (mo) | 0.99 | 0.98-0.99 | <.001 | - | - | - |
| High-risk D/R serostatus | 5.13 | 3.29-8.00 | <.001 | - | - | - |
| D/R serostatus∗ | - | - | - | - | - | - |
| Intermediate risk | - | - | - | |||
| High risk | 5.34 | 3.39-8.40 | <.001 | - | - | - |
| Low risk | 2.02 | 0.62-6.56 | .2 | - | - | - |
| High-risk organ type† | 3.27 | 1.93-5.52 | <.01 | |||
| Age of <18 years at transplant | 2.31 | 1.50-3.57 | <.001 | - | - | - |
| Multivariable Cox regression analysis | ||||||
| Preemptive rituximab | 0.16 | 0.04-0.65 | .011 | 0.25 | 0.06-1.04 | .056 |
| Log-transformed peak EBV viral load (IU/mL) | 1.26 | 1.15-1.38 | <.001 | 1.26 | 1.15-1.37 | <.001 |
| Duration of EBV DNAemia (mo) | 0.99 | 0.99-1.00 | .076 | 0.99 | 0.99-1.00 | .043 |
| Time from SOT to EBV reactivation (mo) | 0.99 | 0.98-1.00 | <.001 | 0.99 | 0.98-0.99 | <.001 |
| D/R serostatus∗ | - | - | - | - | - | - |
| Intermediate risk | - | - | - | - | - | - |
| High risk | 3.08 | 1.78-5.31 | <.001 | 3.11 | 1.82-5.32 | <.001 |
| Low risk | 1.62 | 0.47-5.57 | .4 | 1.71 | 0.50-5.85 | .4 |
| High-risk organ† | 3.71 | 2.03-6.78 | <.001 | 3.69 | 2.03-6.71 | <.001 |
| Age of <18 years at transplant | 1.14 | 0.65-2.01 | .7 | 1.10 | 0.63-1.94 | .7 |